We support one of the strongest combinations of research, clinical and trials expertise in sarcoma anywhere in the world.
The combined clinical and research expertise in LMS at the Marsden and ICR, together with the archive of LMS tissue samples and patient data at the Royal Marsden Hospital, provide a unique and rare opportunity to achieve something remarkable.
We plan to help make ICR and The Royal Marsden one of the global centres of expertise for LMS.
Breakthroughs in cancer treatment of major cancer types using immunotherapy and targeted medicines have not yet been realised in LMS.
Our objective is to help change that.
We support LMS research and studies that:
Use artificial intelligence and pathology expertise to mine the extensive LMS tissue samples and data held at the Royal Marsden Hospital
Discover new bio-markers and define LMS sub-types
Characterise disease pathways using transcriptomic and proteomic techniques
Identify new therapeutic targets
Deliver the basis for precision-based medicine for LMS
We intend that our funding and support model can be replicated by others to develop precision-based therapy for other rare cancers.